

# Clinical trials and research participation at Thirlestaine Breast Centre, Gloucestershire Hospitals NHS Foundation Trust.

R Sidebottom, E Cornford, C Alison, I Lyburn, S Vinnicombe

The Breast Imaging team at GHNHSFT has been active in development of several important national clinical research projects. A state-of-the-art contrast enhanced spectral mammography (CESM) unit, recently installed at Thirlestaine Breast Centre, will enable participation in some of these trials. This will contribute to core Trust strategic objectives for the next 5 years (specifically Driving Research, Centres of Excellence, Outstanding Care and Quality Improvement) and enables our patients to participate in these important studies.



In addition to funding the CESM equipment, the Cobalt charity is supporting the appointment of a trial coordinator within GH R&D to assist with trial management and support the clinical staff.



We will recruit to:

**BRAID:** *Risk Adaptive Breast Screening – A Tailored Imaging Approach.* A randomised trial of imaging modalities for personalised screening of women with dense breasts, including abbreviated MRI and CESM.

CI: Prof Fiona Gilbert, Cambridge



**LORIS:** *Surgery versus Active Monitoring for Low Risk Ductal Carcinoma in Situ (DCIS).* Will utilise the new CESM/biopsy unit.

CI: Dr Matthew Wallis, Cambridge / CRUK Clinical Trials Unit, Birmingham



**SMALL:** *Comparing standard surgical excision of small grade I screen detected cancers with radiological excision with no surgical intervention.* Will utilise the CESM/biopsy unit.

**PHOENIX:** *Identification of biomarkers to predict response for emerging therapeutic agents for triple negative breast cancer.* Utilising MRI.

CI: Andrew Tutt, Institute of Cancer Research, London



**CONTEST:** *Contrast enhanced digital breast tomosynthesis in women with a strong suspicion of breast cancer.* Will utilise CESM. CI: Prof A Evans, Dundee

**NOSTRA:** Feasibility study to assess if residual cancer following neoadjuvant chemotherapy treatment for HER2-positive, ER-negative early breast cancer can be identified by multiple ultrasound-guided tumour bed core biopsies. CI: Prof Daniel Rea. Birmingham. CRUK funded.



We will contribute to:

**OPTIMAM:** Research database of anonymised breast imaging with associated metadata. CI: Prof K Young. National Coordinating Centre for the Physics of Mammography. Participation in this project will facilitate many data intensive research applications.

